178055-17-9

Upstream product

• 150556-72-2 5-(4-hydroxy-benzyl)-3-triphenylmethylthiazolidine-2,4-dione 
• 32380-69-1 2-(2-hydroxyethoxy)-2,3-dihydro-1H-isoindole-1,3-dione 
• 178055-16-8 5-[4-(2-phthalimidooxyethoxy)benzyl]-3-tritylthiazolidine-2,4-dione 

Relevant academic research and scientific papers

Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: Synthesis and structure-activity relationship

Oximes having 5-benzyl-2,4-thiazolidinedione were prepared, and their PPAR γ agonistic activities and blood glucose lowering activities were evaluated. Biaromatic and methyl groups, attached to the oxime moiety, and the ethylene bridge between oxime and p

Oxime derivatives, their preparation and their therapeutic use

Compounds of formula (I): STR1 wherein: R1 is hydrogen or alkyl; R2 is alkylene; R3 is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N-R4, in which R4 is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd): STR2 and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.